Clinical Microbiology and Antimicrobial Chemotherapy. 2013; 15(2):124-130
Ceftaroline fosamil is a novel cephalosporin antibiotic that has a high activity against multiple bacterial pathogens, including important drug-resistant microorganisms. The main benefit of the ceftaroline fosamil compared to other beta-lactams is an activity against methicillin-resistant Staphylococcus aureus (MRSA). In addition, activity against Haemophilus influenzae (including beta-lactamase-producing strains), enteric bacteria, streptococci, and Streptococcus pneumoniae (including multidrugresistant strains) which is comparable to that of third- or fourth-generation cephalosporins makes ceftaroline suitable for the treatment of community-acquired pneumonia and skin and skin structure infections. This paper reviews characteristics of ceftaroline fosamil and clinical studies providing evidence of its efficacy in patients with the above infections.